Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evacuation of Lobar Intracranial Hemorrhage Using Microsurgical Technique (ELIMINATE) (ELIMINATE)

8. juli 2026 oppdatert av: Dr. Michael D Hill

Evacuation of Lobar Intracranial Hemorrhage Using Microsurgical Technique (ELIMINATE): A Prospective Observational Surgical Cohort Study of Feasibility, Safety, and Radiographic Outcomes

ELIMINATE is a cohort study, phase 2A, designed to determine whether a standardized microsurgical procedure to evacuate spontaneous lobar intracranial hemorrhage (ICH) is feasible, safe and surgically efficacious in achieving a postoperative residual ICH volume <15cc on 24-hour postoperative CT imaging.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

The primary objective of ELIMINATE, a prospective, single-centre, observational surgical cohort study, is to determine whether a standardized microsurgical procedure to evacuate spontaneous lobar intracranial hemorrhage (ICH) is feasible, safe and surgically efficacious in achieving a postoperative residual ICH volume <15cc on 24-hour postoperative CT imaging. The secondary objectives include assessment of tool-tissue forces and bleeding, residual ICH volume postoperatively, and determining the recruitment rate for patients with spontaneous lobar ICH.

The primary clinical outcome will be the proportion of enrolled patients achieving residual ICH volume <15cc on postoperative CT scan at 24 hours. Key outcomes are:

Radiographic: percent evacuation; residual volume (continuous + dichotomized). Functional: mRS at 6 months; EQ-5D-5L at 6 months; mortality at 30 and 180 days.

Intraoperative: force metrics; bleeding quantification; operative time; blood loss.

Feasibility: recruitment rate; proportion operated ≤16 hours; completeness of imaging.

Safety: symptomatic rebleeding ≤72h; postoperative deficits; infections; unplanned OR return; 30-day mortality.

A maximum of 27 adult patients will be enrolled.

Inclusion criteria:

  • Adults > 18 years
  • CT evidence of acute, spontaneous lobar ICH defined as located <1cm from the cortical surface
  • ICH volume is >30cc but <80cc as measured by (length x width x height)/2
  • GCS 5-14 at presentation
  • NIHSS >5
  • Surgery deemed to be feasible within 16h of symptom onset

Exclusion criteria:

  • Underlying secondary etiology (AVM, tumor, etc. if known or identifiable acutely)
  • Intraventricular extension estimated to involve >50% of the lateral ventricle
  • Preoperative disability that will affect outcome as measured by modified Rankin Scale score (mRS>1 at baseline)
  • Individuals presenting with GCS <5 at presentation
  • Primary basal ganglia hemorrhage with lobar extension
  • End-stage organ failure or life expectancy <6 months
  • For patients in whom the treating clinical team elects to proceed with surgical evacuation as part of clinical care, a standardized evacuation of the hematoma will be performed using neuronavigation for optimal craniotomy planning, microsurgical technique and SmartForceps System for quantifiable intraoperative data.

This study consists of one 180-day study period for each subject. Subjects will be hospitalized for care after their lobar ICH and surgical intervention according to the current standard of care. Subjects will undergo phone assessment on Day 180 by a trained assessor.

Studietype

Observasjonsmessig

Registrering (Antatt)

27

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Alberta
      • Calgary, Alberta, Canada, T2N 2T9
        • Foothills Medical Centre

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Adults with spontanous lobar ICH who are appropriate for surgical evacuation.

Beskrivelse

Inclusion Criteria:

  • • Adults > 18 years

    • CT evidence of acute, spontaneous lobar ICH defined as located <1cm from the cortical surface
    • ICH volume is >30cc but <80cc as measured by (length x width x height)/2
    • GCS 5-14 at presentation
    • NIHSS >5
    • Surgery deemed to be feasible within 16h of symptom onset

Exclusion Criteria:

  • • Underlying secondary etiology (AVM, tumor, etc. if known or identifiable acutely)

    • Intraventricular extension estimated to involve >50% of the lateral ventricle
    • Preoperative disability that will affect outcome as measured by modified Rankin Scale score (mRS>1 at baseline)
    • Individuals presenting with GCS <5 at presentation
    • Primary basal ganglia hemorrhage with lobar extension
    • End-stage organ failure or life expectancy <6 months
    • For patients in whom the treating clinical team elects to proceed with surgical evacuation as part of clinical care, a standardized evacuation of the hematoma will be performed using neuronavigation for optimal craniotomy planning, microsurgical technique and SmartForceps System for quantifiable intraoperative data.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Single cohort deisgn
Surgical evacuation of ICH using microsurgical technicque.
Microsurgical hematoma evacuation using microscope and neuronavigation

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Recruitment rate
Tidsramme: Quarterly from study onset through study completion with the final recruitment rate recorded at the end of study; total time 12 months
Total recruitment will be recorded each month and report as number of patients recruited per calendar month as an average for duration of the study. The numerator will be the cumulative total number of pateints recruitment and the denominator will be the number of months elapsed since study start. The demoninator can be a fractional number; the numerator will also be a positive integer.
Quarterly from study onset through study completion with the final recruitment rate recorded at the end of study; total time 12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Residual hematoma volume
Tidsramme: Up to 2 days after enrolment; post-operative core lab assessment of the 18-54 hour follow-up CT brain scan. The Core Lab will measure residual hematoma volume using summative planimetry over the volume of each CT scan slice image.
Residual hematoma volume
Up to 2 days after enrolment; post-operative core lab assessment of the 18-54 hour follow-up CT brain scan. The Core Lab will measure residual hematoma volume using summative planimetry over the volume of each CT scan slice image.
modified Rankin Scale Score
Tidsramme: at 90 days and 180 days after enrolment.
mRS score is an integer scale ranging from 0 to 6 (7 point interval scale). Lower score are better and the highest score (6) implies death
at 90 days and 180 days after enrolment.
EuroQoL
Tidsramme: at 90 days and 180 days after randomization
EQ5D-5L is a 5 domain scale, with a 5 point Likert scale for the quesiton in each domain. It addresses quality of life and the final score (the EQ5D Index) is adjusted by country to local norms using standardized methodology. Higher index scores inply a higher quality of life.
at 90 days and 180 days after randomization

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Forceps forces
Tidsramme: Perioperative/peri-procedural
Intra-operative forceps forces during microsurgery. These devices have haptic measurement capability and will reocrd the degree of force each time dissection or cautery are used. Recording will be conducted during the entire operative procedure.
Perioperative/peri-procedural

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. september 2026

Primær fullføring (Antatt)

31. desember 2027

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

14. juni 2026

Først innsendt som oppfylte QC-kriteriene

8. juli 2026

Først lagt ut (Faktiske)

13. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Within 2 years of publication, the primary data will posted in a public data respository.

IPD-delingstidsramme

Within 2 years of study end date.

Tilgangskriterier for IPD-deling

All researchers after approval by the study steering committee.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • ANALYTIC_CODE
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere